Table 1 Baseline participant characteristics.
From: A mixed-methods pilot study of handheld fan for breathlessness in interstitial lung disease
Intervention group (N = 15) | Control group (N = 15) | |
|---|---|---|
Age, years | 73.7 ± 10.5 | 71.7 ± 7.3 |
Gender, female:male | 8:7 | 6:9 |
BMI, kg/m2 | 28.9 ± 5.2 | 29.2 ± 5.3 |
Ever smoker, n (%) | 9 (60) | 10 (67) |
Duration of diagnosis, years | 3 (2, 8) | 3 (2, 6) |
Diagnosis, n (%) | ||
IPF | 5 (33) | 5 (33) |
Non-IPF | 10 (67) | 10 (67) |
Asbestosis | – | 1 |
CTD-ILD | 6 | 3 |
Drug-induced ILD | 1 | – |
Fibrotic HP | 1 | 3 |
Non-specific interstitial pneumonia | 1 | 1 |
Unclassifiable ILD | 1 | 2 |
FEV1/FVC | 77.6 ± 6.0 | 79.3 ± 8.0 |
FEV1 (% pred) | 78.2 ± 18.2 | 71.3 ± 15.0 |
FVC (% pred) | 77.6 ± 18.0 | 68.2 ± 15.3 |
DLCO (% pred) | 42.1 ± 11.5 | 41.7 ± 12.2 |
mMRC dyspnoea score | 2 (2, 3) | 2 (2, 3) |
Domiciliary oxygen therapy, n (%) | 2 (13) | 5 (33) |
ILD therapies, n (%) | ||
Anti-fibrotic therapy | 4 (27) | 4(27) |
Immunosuppressant therapy | 6 (40) | 7 (47) |
Inhaler therapies, n (%) | ||
Inhaled corticosteroid + long-acting beta-agonist | 3 (20) | 1 (7) |
Long-acting muscarinic antagonist | 1 (7) | 1 (7) |
Short-acting beta-agonist | 5 (33) | 2 (13) |
Pulmonary rehabilitation in the previous 6 months, n (%) | 7 (47) | 8 (53) |
